Adverum Biotechnologies Inc
ADVM4.360USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
95.92MMarket Cap
LossP/E TTM
More Details of Adverum Biotechnologies Inc Company
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. It discovers and develops gene therapy product candidates that provide durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration (wet AMD). Its other partnered programs include BGTF-027 (AAV.7m8-L-opsin), a gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (BCM) via a single IVT injection.
Adverum Biotechnologies Inc Info
Ticker SymbolADVM
Company nameAdverum Biotechnologies Inc
IPO dateJul 31, 2014
CEOFischer (Laurent)
Number of employees155
Security typeOrdinary Share
Fiscal year-endJul 31
Address100 Cardinal Way
CityREDWOOD CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94063
Phone16506491004
Websitehttps://adverum.com/
Ticker SymbolADVM
IPO dateJul 31, 2014
CEOFischer (Laurent)
Company Executives of Adverum Biotechnologies Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Rabia Gurses Ozden, M.D.
Dr. Rabia Gurses Ozden, M.D.
Chief Medical Officer
Chief Medical Officer
76.88K
--
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Chief Development Officer
Chief Development Officer
52.75K
-1.72%
Ms. Linda M. Rubinstein
Ms. Linda M. Rubinstein
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jason L. Mitchell
Mr. Jason L. Mitchell
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Kishor Peter Soparkar, J.D.
Mr. Kishor Peter Soparkar, J.D.
Chief Operating Officer
Chief Operating Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Rabia Gurses Ozden, M.D.
Dr. Rabia Gurses Ozden, M.D.
Chief Medical Officer
Chief Medical Officer
76.88K
--
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Chief Development Officer
Chief Development Officer
52.75K
-1.72%
Ms. Linda M. Rubinstein
Ms. Linda M. Rubinstein
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jason L. Mitchell
Mr. Jason L. Mitchell
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Kishor Peter Soparkar, J.D.
Mr. Kishor Peter Soparkar, J.D.
Chief Operating Officer
Chief Operating Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Dec 12
Updated: Fri, Dec 12
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Principia Wealth Advisory, LLC
9.19%
TCG Crossover Management, LLC
7.56%
Stern (Augustus)
5.06%
Rush (Ryan Bradford)
4.76%
The Vanguard Group, Inc.
3.95%
Other
69.49%
Shareholders
Shareholders
Proportion
Principia Wealth Advisory, LLC
9.19%
TCG Crossover Management, LLC
7.56%
Stern (Augustus)
5.06%
Rush (Ryan Bradford)
4.76%
The Vanguard Group, Inc.
3.95%
Other
69.49%
Shareholder Types
Shareholders
Proportion
Investment Advisor
24.13%
Individual Investor
10.89%
Hedge Fund
5.43%
Venture Capital
4.81%
Investment Advisor/Hedge Fund
2.86%
Research Firm
1.71%
Private Equity
1.65%
Corporation
0.82%
Other
47.71%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
182
16.32M
101.41%
+2.21M
2025Q3
185
14.10M
102.19%
-56.36K
2025Q2
185
14.10M
105.81%
-2.50M
2025Q1
186
16.29M
103.64%
-5.36M
2024Q4
185
15.84M
101.65%
-1.68M
2024Q3
194
18.14M
102.51%
-10.73K
2024Q2
188
18.00M
98.58%
-1.03M
2024Q1
200
16.84M
79.16%
+412.75K
2023Q4
194
6.42M
87.68%
-161.10K
2023Q3
230
6.58M
91.98%
-234.50K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Principia Wealth Advisory, LLC
2.03M
9.67%
+332.30K
+19.58%
Jun 30, 2025
TCG Crossover Management, LLC
1.80M
8.56%
--
--
Jun 30, 2025
Stern (Augustus)
1.12M
5.32%
+1.12M
--
Oct 29, 2024
Rush (Ryan Bradford)
1.05M
5%
+1.05M
--
Dec 17, 2024
The Vanguard Group, Inc.
883.94K
4.21%
-145.39K
-14.12%
Jun 30, 2025
5AM Ventures
541.67K
2.58%
--
--
Jun 30, 2025
Versant Ventures
506.82K
2.42%
--
--
Jun 30, 2025
Goldman Sachs & Company, Inc.
470.02K
2.24%
+60.70K
+14.83%
Jun 30, 2025
Renaissance Technologies LLC
570.67K
2.72%
+411.10K
+257.63%
Jun 30, 2025
Pale Fire Capital SE
358.72K
1.71%
-9.54K
-2.59%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Global X Russell 2000 ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
0%
Dimensional US Core Equity 1 ETF
0%
Proshares Ultra Russell 2000
0%
View more
iShares Micro-Cap ETF
Proportion0.01%
Fidelity Enhanced Small Cap ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
DFA Dimensional US Core Equity Market ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 18, 2024
Merger
10→1
Mar 18, 2024
Merger
10→1
Mar 18, 2024
Merger
10→1
Mar 18, 2024
Merger
10→1
Date
Type
Ratio
Mar 18, 2024
Merger
10→1
Mar 18, 2024
Merger
10→1
Mar 18, 2024
Merger
10→1
Mar 18, 2024
Merger
10→1
FAQs
Who are the top five shareholders of Adverum Biotechnologies Inc?
The top five shareholders of Adverum Biotechnologies Inc are:
Principia Wealth Advisory, LLC holds 2.03M shares, accounting for 9.67% of the total shares.
TCG Crossover Management, LLC holds 1.80M shares, accounting for 8.56% of the total shares.
Stern (Augustus) holds 1.12M shares, accounting for 5.32% of the total shares.
Rush (Ryan Bradford) holds 1.05M shares, accounting for 5.00% of the total shares.
The Vanguard Group, Inc. holds 883.94K shares, accounting for 4.21% of the total shares.
Principia Wealth Advisory, LLC holds 2.03M shares, accounting for 9.67% of the total shares.
TCG Crossover Management, LLC holds 1.80M shares, accounting for 8.56% of the total shares.
Stern (Augustus) holds 1.12M shares, accounting for 5.32% of the total shares.
Rush (Ryan Bradford) holds 1.05M shares, accounting for 5.00% of the total shares.
The Vanguard Group, Inc. holds 883.94K shares, accounting for 4.21% of the total shares.
What are the top three shareholder types of Adverum Biotechnologies Inc?
The top three shareholder types of Adverum Biotechnologies Inc are:
Principia Wealth Advisory, LLC
TCG Crossover Management, LLC
Stern (Augustus)
Principia Wealth Advisory, LLC
TCG Crossover Management, LLC
Stern (Augustus)
How many institutions hold shares of Adverum Biotechnologies Inc (ADVM)?
As of 2025Q4, 182 institutions hold shares of Adverum Biotechnologies Inc, with a combined market value of approximately 16.32M, accounting for 101.41% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.78%.
What is the biggest source of revenue for Adverum Biotechnologies Inc?
In --, the -- business generated the highest revenue for Adverum Biotechnologies Inc, amounting to -- and accounting for --% of total revenue.
